News

Discover-2 is a randomized, double-blind, double-dummy study conducted in patients randomized to vancomycin allowed to switch to oral linezolid after three days of IV vancomycin therapy. The study

Regional distributors join InVitria’s worldwide distributors including Sigma-Aldrich and Thermo Fisher Scientific. The company’s distribution network will provide regional distribution options for customers in North America, Europe, Asia,

Elsevier’s External link e-learning ICD-10 comprises ICD-10 Roadmap and educational resources, that will be integrated into Care Communications’ offerings. The ICD-10 Roadmap is divided into four phases of

APN301 is a recombinant fusion protein consisting of the humanized anti-GD2 monoclonal antibody hu14.18 fused to the cytokine interleukin-2 (IL2). APN301 will be administered along with GM-CSF and

AL-408 has been proven to have potent neuroprotective effects in a number of in vitro and in vivo models of neurotoxicity, the data from pre-clinical studies says. In

Aptiv Solutions will manage the Galena Phase 3 trial, PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment). The

Lodotra, which is currently approved for marketing in 16 European countries is a modified (delayed)-release formulation of low-dose prednisone. Circadian Administration of Prednisone in RA (CAPRA-2), 12-week, double-blind,

According to the arm Phase II study which comprised 126 patients receiving BIBF 1120 as first-line treatment in combination with mFOLFOX6 showed a median progression-free survival of 10.6

Under the deal, both the firms will focus on developing three of Proximagen’s programmes, with the aim of identifying novel innovative therapies for serious diseases such as epilepsy,